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Letter to the EditorCross-country migration linked to people who inject drugs challenges
the long-term impact of national HCV elimination programmesTo the Editor:
As of 2018, the majority of Western European countries –
including Spain – have lifted restrictions to therapy based on
disease severity in the context of HCV infections.1 Long overdue,
most national elimination programmes now also include access
to care for people who inject drugs (PWID),2 who are at the core
of ongoing HCV transmission.3 Macías et al.4 have recently
shown in this Journal that high viral cure rates can be achieved
in this group, hereby providing evidence that targeting PWID in
treatment programmes is worthwhile. However, the extent to
which such national efforts can reduce the HCV burden not only
depends on the uptake into care and treatment success rates, it
is also determined by the relative importance of within-country
transmission and virus importation from elsewhere.
As the chronic nature of most HCV infections hampers reli-
ably reconstructing contact networks from patient interviews,
virus genetic data can be a valuable alternative source of infor-
mation for elucidating the geographic history of virus lineages
(e.g. 5,6). Using such data, we have recently shown that for
the most prevalent subtype among PWID in Spain (40%,7),
HCV1a, infections often link to infections abroad – in recent
years >50% link to Western European countries, mostly Euro-
pean Union (EU) member states – as opposed to other infections
within Spain.8 Hence, reducing HCV1a prevalence and spread
across Europe will help to consolidate the impact of Spanish
efforts to reduce the HCV burden.
To investigate whether this is a general pattern that also
holds for the second most prevalent subtype among PWID in
Spain (26.5%,7), HCV3a, we analysed newly generated HCV3a
genome data covering parts of the NS5A and/or NS5B genes
from 196 HCV3a-infected patients sampled between April
2014 and April 2017 across Spain (GenBank: accession numbers
MN227780 - MN228016). Of the 60% for whom information on
the probable route of transmission was available, 81.8%
reported injecting drug use. These sequences were comple-
mented with a background dataset of publicly available data
from GenBank (totalling 2752 taxa), and analysed as previously
described.5,8 The Ethics Committee of the San Cecilio Hospital,
Granada, approved the study, and no informed consent was
required as patient information was anonymised and de-identi-
fied prior to analysis.
As for HCV1a,8 we found that the transmission network size
structure is not dominated by a few large exclusively Spanish
transmission networks, meaning that HCV3a transmission hot
spots in Spain more often bridge to networks abroad rather than
being connected domestically. Whereas we previously found an
increasing importance of European lineages in seeding the
HCV1a epidemic in Spain,8 our current reconstructions showed
that HCV3a virus movements from within the EU account forJournal of Hepatology 2
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time. The number of imported HCV3a infections per year from
other EU member states – which is a lower bound estimate –
has increased on average by 1 to 4 per year, totalling 125
(95% credible interval: 92–158) introductions (Fig. 1). The trend
and magnitude are similar to those for HCV1a, for which the
number of lineage introductions totals 114 (95% credible inter-
val: 72–156) (Fig. 1).
The Spanish national strategy against HCV is based on a com-
bination of factors, including a focus on increased screening and
diagnosis, enhancing the treatment infrastructure, the availabil-
ity of improved therapeutic regimens and targeting the groups
at highest risk of transmitting HCV, including PWID.9–11 Despite
existing challenges and policy differences between regions, this
multifactorial approach has led to Spain being one of the few
countries in Europe that are reported to be on track to meet
the World Health Organization HCV elimination targets by
2030.12 As more recent subtype 1a and 3a infections are associ-
ated with illicit (injecting) drug use (e.g. 3), targeting this group
that drives onwards spread, and for which Macías et al.4 have
demonstrated that treatment can be highly effective, is most
desirable in many countries. However, across Europe, most
countries have yet to embrace the universal treatment para-
digm, and even more are yet to develop and implement a
national strategy towards the elimination of HCV.1 Our current
and previous results8 illustrate that in the absence of the latter,
HCV will rapidly be re-seeded in the Spanish PWID population,
challenging the long-term impact of the current Spanish inter-
vention efforts. This demonstrates that there are beneficial
scale-effects to implementing concurrent national efforts in
the EU and elsewhere, without which the ultimate goal, namely
eliminating HCV, will likely remain elusive.Conflict of interest
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Fig. 1. Frequent importation of HCV subtype 1a and 3a lineages into Spain
mostly from other countries within the European Union. The lines
correspond to the average cumulative number of introduction events for
these subtypes from other countries within the European Union into Spain,
with the shaded areas indicating the uncertainty (95% credible interval). Grey
colors pertain to subtype 1a, and blue colors to subtype 3a.
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